Stay updated on Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial page.
Latest updates to the Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial page
- Check6 days agoChange DetectedFooter revision label updated from v3.3.1 to v3.3.2; no user-facing content or functionality appears affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check13 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not be about the study; updated the revision reference to v3.3.1 (replacing v3.2.0).SummaryDifference0.1%
- Check21 days agoChange DetectedDeleted the government funding/operating status notice from the page. The core study details remain unchanged.SummaryDifference0.3%
- Check35 days agoChange DetectedThe screenshots appear to reflect only layout and formatting updates with no changes to the core study content (eligibility criteria, locations, interventions, or primary/secondary outcomes). No new or altered critical information that would affect a participant's decision to join or a site's participation has been observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check63 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference2%
- Check71 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%
Stay in the know with updates to Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial page.